Key result
The spinal cord, particularly via the actions of spinal angiotensin II, represents a potential therapeutic target to mitigate sympathetic vasomotor overactivity in cardiovascular diseases.
Why the study?
Sympathoexcitation is common in several cardiovascular diseases, prompting the need to explore the spinal cord as a potential therapeutic target to reduce sympathetic vasomotor overactivity.
The spinal cord, specifically pathways involving spinal angiotensin II, may serve as a novel therapeutic target to reduce sympathetic vasomotor overactivity in cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
Spinal angiotensin II modulation remains hypothesis-generating; clinical trials needed before any practice consideration.
The control of sympathetic vasomotor activity involves a complex network within the brain and spinal circuits. An extensive range of studies has indicated that sympathoexcitation is a common feature in several cardiovascular diseases and that strategies to reduce sympathetic vasomotor overactivity in such conditions can be beneficial. In the present mini-review, we present evidence supporting the spinal cord as a potential therapeutic target to mitigate sympathetic vasomotor overactivity in cardiovascular diseases, focusing mainly on the actions of spinal angiotensin II on the control of sympathetic preganglionic neuronal activity.
No takes yet. Share an insight, caveat, or question.
Milanez et al. (2020) conducted a review in Cardiovascular diseases with sympathetic vasomotor overactivity. Targeting spinal cord / spinal angiotensin II was evaluated. The spinal cord, particularly via the actions of spinal angiotensin II, represents a potential therapeutic target to mitigate sympathetic vasomotor overactivity in cardiovascular diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: